Open Label Study of Long Term Evaluation Against LDL-C Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1324 participants.
Also called NCT01439880
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,324 participants
- Sponsor
- Registry
-
NCT01439880 -
2011-001915-29
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Czechia, Denmark, Finland, Germany, Hong Kong SAR China, Hungary, Japan, Netherlands, Norway, Singapore, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01439880. Randomized; no masking; primary purpose treatment. Start 2011-10-07 (actual); primary completion 2018-06-20 (actual). Results posted on 2019-07-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open Label Study of Long Term Evaluation Against LDL-C Trial
- Acronym
- OSLER
- Condition
- Hypercholesterolemia
- Intervention (Biological)
- Evolocumab
- Intervention (Other)
- Standard of care
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01439880- Content hash
e3b1d4c8d04394e3d8a9de6cce316cd07fbc35642d936b98e10c10eba3fbed50